Overview
The aim of this observational study is to assess the level of adherence to guideline recommendations regarding the management of patients with Heart Failure with Reduced Ejection Fraction (HFrEF); - the safety profile of the implementation of recommended treatments; - to monitor treatment patterns of patients with acute hert failure (HF); - to monitor treatment patterns of all patients with chronic HF irrespective of the level of ejection fraction (EF).
Description
Observational, prospective, multicenter study conducted in a large, representative sample of Italian cardiology centers.
Phases 1:
- First educational intervention to discuss the recommendations of guidelines and treatment patterns in specific phenotypes of patients.
- Data collection for 3 months or up to 30 consecutive patients with chronic HF or acute HF (both de novo and worsening).
- Evaluation of the primary and secondary end-points of the study at 6 months after enrollment. Modifications of treatments will be monitored during the 6 months follow-up.
- Second educational intervention to share the results of the first enrollment period of the study focusing the attention on existing gaps between guidelines recommendations and clinical practice.
- New data collection for other 3 months or up to 30 consecutive patients with chronic HF or acute HF (both de novo and worsening).
- Additional evaluation of the primary and secondary end-points of the study at 6 months after enrollment. Modifications of treatments will be monitored during the 6 months follow-up.
- 12-month follow-up for all patients included in both enrolment phases of the study.
Eligibility
Inclusion Criteria:
- Age ≥18 years old.
- Males and females at birth.
- Any ejection fraction level (level of ejection fraction measured in the 6 months preceding enrollment).
- Ambulatory chronic HF or Hospitalized de-novo or worsening HF.
- Signed informed consent
Diagnosis will be made by the local attending physician following the ESC guidelines
recommendations.
Exclusion Criteria:
1. Active neoplasia or very severe disease compromising short-medium term life
expectancy.
2. Participation in interventional studies.
3. Patients already enrolled into the study from another participating center or in the
previous enrolling phase.